xieqing

Xieqing Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative peptide drugs for metabolic and endocrine diseases. The company leverages its proprietary long-acting peptide technology platform to create multi-target agonists that address complex metabolic pathways. Its lead candidate, XQ-001, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently undergoing Phase 2 clinical trials for obesity and type 2 diabetes. Xieqing's pipeline also includes XQ-002, a dual GLP-1/GIP receptor agonist, and other candidates for conditions such as NASH. Founded by industry veterans with extensive experience in peptide chemistry, the company has secured significant backing from prominent investors like Qiming Venture Partners. Xieqing aims to provide more effective and convenient treatment options for the global population suffering from chronic metabolic disorders.